Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

Not Disclosed Neuroscience and Pain 2 is under clinical development by Evotec and currently in Phase I for Unspecified Neurologic Disorders.

Evotec SE (NASDAQ:EVO – Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $4.16, but opened at $4.32. Evotec shares last traded at $4.29, with a ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

German stocks are a bit subdued Tuesday morning with investors making cautious moves amid a lack of significant triggers. Data on ...

QUANTRO’s proprietary time-resolved functional transcriptomic discovery platform accelerates target screening for complex indications in oncology ...

US biotech Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been "unwilling to engage with us to explore a potential combination." Halozyme made ...

Despite macroeconomic uncertainty and geopolitical instability, the S&P 500 rallied to new all-time highs in 2024. Unfortunately, there were plenty of stocks that missed out on the bull market rally.

The JV has been formed German pharma companies Boehringer Ingelheim and Evotec with in vitro diagnostics specialist bioMérieux, with the objective of developing new antimicrobial drugs backed by ...